6533b821fe1ef96bd127bab6
RESEARCH PRODUCT
Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.
Giorgio StassiMatilde TodaroNadia CaccamoSerena MeravigliaFrancesco Dielisubject
business.industrymedicine.medical_treatmentT cellImmunologyCancerTRAILImmunotherapyNKG2Dmedicine.diseaseVγ9Vδ2 T cellsIn vitroNKG2Dmedicine.anatomical_structureImmune systemOncologyImmunologymedicineImmunology and AllergyConventional chemotherapycytotoxicitycolon cancer-initiating cellsCytotoxicitybusinessAuthor's Viewdescription
According to common beliefs, conventional anticancer chemotherapy is deleterious for the immune system. We have recently provided in vitro evidence indicating that conventional chemotherapy may potentiate, rather than impair, the long-term efficacy of γδ T cell-based anticancer immunotherapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-09-01 | Oncoimmunology |